Teva sells US copies of 5 of the blockbuster drugs on this tracker, is approved for 2 more, and has 4 filed or in development. Those brands earned $47.8B in 2025. Of the 70 makers we follow, 3 are lined up to copy more of these drugs.
| Drug | Teva's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| Stelara SelarsdiBiosimilar · Johnson & Johnson · US LOE 2025 | FDA-approved 16 Apr 2024; launched 21 Feb 2025; interchangeable With Alvotech |
7 on sale · 0 approvedof 7 other makers listed | $6.1B |
| FarxigaGeneric · AstraZeneca · US LOE 2026 | FDA-approved 6 Apr 2026; launched Apr 2026 | 1 on sale · 13 approvedof 14 other makers listed | $8.4B |
| PomalystGeneric · Bristol Myers Squibb · US LOE 2026 | FDA-approved 4 May 2022; launched Mar 2026 | 3 on sale · 6 approvedof 10 other makers listed | $2.7B |
| JanuviaGeneric · Merck · US LOE 2026 | FDA-approved 30 Dec 2025; launched May 2026; first filer; FDA has not decided whether it keeps 180-day shared exclusivity. Filed as Watson | 1 on sale · 1 approvedof 2 other makers listed | $2.5B |
| OpsumitGeneric · Johnson & Johnson · US LOE 2026 | FDA-approved 8 Jun 2026; launched Jun 2026 | 1 on sale · 10 approvedof 11 other makers listed | $2.3B |
| Drug | Teva's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| Prolia PonlimsiBiosimilar · Amgen · US LOE 2025 | FDA-approved 27 Mar 2026; interchangeable | 7 on sale · 2 approvedof 10 other makers listed | $4.4B |
| Xgeva DegevmaBiosimilar · Amgen · US LOE 2025 | FDA-approved 25 Sep 2026; launch expected in the coming months; interchangeable | 6 on sale · 3 approvedof 10 other makers listed | $2.1B |
| Drug | Teva's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| Simponi AVT05Biosimilar · Johnson & Johnson · US LOE 2026 | Filed with the FDA. FDA turned it down in Oct 2025 over factory issues only; resubmitted Jun 2026 With Alvotech |
0 on sale · 1 approvedof 1 other maker listed | $2.7B |
| CabometyxGeneric · Exelixis · US LOE 2031 | Filed with the FDA; settled; US entry allowed from 1 Jan 2031 | 0 on sale · 3 approvedof 5 other makers listed | $2.1B |
| Entyvio AVT16Biosimilar · Takeda · US LOE 2032 | Filed with the FDA; in litigation, sued Sep 2026. FDA decision expected Q1 2027 With Alvotech |
0 on sale · 0 approvedof 2 other makers listed | ≈$6.0B |
| Drug | Teva's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| Ocrevus PB018Biosimilar · Roche · US LOE 2029 | Early development. Phase 1 planned for Oct 2026 With Polpharma |
0 on sale · 0 approvedof 2 other makers listed | ≈$8.4B |
Copies not yet on sale, by the earliest year each could reach the US market: a settlement or court date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.
The brand owner's US sales, as it reports them. They show how fast copies took the market, not Teva's own sales. See the launch tracker →
Each row is a copy Teva sells, holds an approval for, has filed, or is developing, for one of the 63 blockbuster drugs this site tracks. It is not Teva's full portfolio. "Other makers listed" counts the other companies on the same drug's list: how many sell a copy and how many more hold an approval. Brand owners and the FDA don't always name every filer, so a list can be incomplete; the drug page says so where we know.
2025 sales are what each brand earned, the size of the market at stake. They are not Teva's sales; several makers usually share a market once copies launch.
112 US applications awaiting FDA approval, 65 of them tentatively approved (31 Mar 2026), across all products, not just the drugs tracked here.
Every row is sourced on its drug's page: FDA Orange Book and Purple Book approvals, company releases and filings for launches, and court and company records for settlements. Company facts: SEC company tickers; Teva 10-K 2025, Teva 10-Q, Q1 2026, Teva 10-Q, Q2 2026.